Monoclonal antibody therapy for COVID-19 – Part 3

In Part 3 of this series on monoclonal antibody therapies for COVID-19, our expert panel continues their discussion on concerns about the efficacy and distribution of these treatment options. They respond to the FDA’s recent Emergency Use Authorization (EUA) for monoclonal antibodies.

 

Guest speakers:
Azra Behlim, PharmD, MBA
Senior Director
Pharmacy Sourcing and Program Services 
Vizient

Stacy Lauderdale, PharmD
Senior Director
Drug Information
Vizient

Steve Rudner, PharmD, MS
Director
Pharmacy Network Contracting
Vizient

 

Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources
Vizient

 

Show Notes:
[00:37] Identifying the right patients – best practices
[03:10] The access challenge
[05:54] Plenty of availability
[06:10] COVID vaccination and use of monoclonal antibody therapy
[06:37] Post-infusion management

 

Links | Resources:

Press release and information from FDA Click here

Information from FDA on EUA for monoclonal antibody therapy Click here

ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here

[ For more information, contact: ASPRstakeholder@HHS.gov ]

JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here

 

Subscribe Today!

Apple Podcasts

Spotify

Android

Google Podcasts

Stitcher

RSS Feed